webinar register page

Immunic: Multiple Sclerosis R&D Webcast
Immunic’s management will be joined by renowned key opinion leaders to discuss the unmet need as well as recent scientific findings in the multiple sclerosis space, including:

- Today’s treatment options and the unmet medical need for multiple sclerosis
- The latest scientific findings, providing clear evidence of a direct link between Epstein-Barr virus and multiple sclerosis
- Preclinical and clinical progress of Immunic’s selective oral DHDOH inhibitor, vidofludimus calcium (IMU-838)
- The company’s ongoing clinical phase 3 ENSURE and phase 2 CALLIPER programs in relapsing and progressive multiple sclerosis, respectively

Nov 17, 2022 11:00 AM in Eastern Time (US and Canada)

Webinar logo
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Jessica Breu.